Bilateral branch retinal vein occlusion following the diagnosis of mild coronavirus disease

Karasu, Buğra; Kesim, Enes

doi:10.5935/0004-2749.20230017

Cited by 4 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Final VA not specified Mahjoub et al 38 1 (F) 38 Moderate 3/10 (∼20/65) 4 weeks Not reported Not reported OCT, OCTA, FA CSCR Discontinuation of steroids VA 8/10 (20/25) Sanjay et al 39 1 (F) 42 Mild OD: 20/40, OS: 20/20 12 days Elevated ESR and CRP No OCT, FA CSCR Discontinuation of inhaled steroids Decreased subretinal fluid. VA OD: 20/25, OS: 20/20 Karasu et al 40 1 (M) 48 Moderate OD: 100/100, OS: 20/100 2 months Elevated D-dimer No OCT, FA BRVO Not reported VA OD 40/100, OS 30/100 Nourinia et al 41 1 (F) 60 Severe 20/200 10 days Elevated ESR, CRP, D-dimer, ferritin No OCT, FA BRVO IVI bevacizumab Not reported Duff et al 42 1 (F) 74 Not reported Not reported Not reported Not reported Not reported OCT, FA, FAF...…”

Section: Methodsmentioning

confidence: 98%

The spectrum of COVID-19-associated chorioretinal vasculopathy

Carletti,

Shah,

Bair

et al. 2023

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 98%

The spectrum of COVID-19-associated chorioretinal vasculopathy

Carletti,

Shah,

Bair

et al. 2023

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

Case Report: Branch retinal vein occlusion following COVID-19 vaccination and SARS-CoV-2 infection while taking oral contraceptives

Muto,

Sakamoto,

Machida

et al. 2024

F1000Res

View full text Add to dashboard Cite

Oral contraceptive use, vaccination for Coronavirus disease 2019 (COVID-19), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are risk factors for venous thromboembolism. Branch retinal vein occlusion (BRVO) generally develops mid-60s patients. Herein, we present a case of BRVO caused by the above mentioned risk factors in a young woman. To the best of our knowledge, this is the first report about BRVO associated with oral contraceptives, COVID-19 vaccination, and SARS-CoV-2. A 21-year-old woman presented with loss of visual acuity in her right eye for 10 days. She had been receiving oral contraceptives for 2 years for oligomenorrhea before noticing ophthalmological symptoms. Despite having received two doses of an mRNA COVID-19 vaccine, she contracted COVID-19 and developed fever, sore throat, cough, low back pain, and general malaise about 40 days before the initial visit. However, only cough persisted for more than a month. The right eye showed BRVO with macular edema (ME). She did not smoke nor had diabetes or hypertension. Blood test results, including cardiolipin antibody IgG, were normal. She was treated with an intravitreal aflibercept injection. ME in the fundus showed rapid improvement and resolution. Although more than 20 months have passed since the first injection, there has been no relapse of ME. The combination of oral contraceptive use, COVID-19 vaccination, and subsequent SARS-CoV-2 infection could induce the development of venous thromboembolism, thereby leading to BRVO. Given that cases of COVID-19 have increased globally, patients with retinal vein occlusion who use oral contraceptives are likely to be encountered more frequently.

show abstract

Development of Branch Retinal Vein Occlusion Following COVID-19 Vaccination and Subsequent SARS-CoV-2 Infection While Taking Oral Contraceptives

Muto

Sakamoto

Machida

et al. 2022

Preprint

View full text Add to dashboard Cite

Objectives Oral contraceptive use, vaccination for coronavirus disease 2019 (COVID-19), and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are all risk factors for venous thromboembolism (VTE). Although, in general, branch retinal vein occlusion (BRVO) develops during the mid-60s in general, we present a case of BRVO caused by the abovementioned risk factors in a young woman. To the best of our knowledge, this is the first report about BRVO associated with oral contraceptives, COVID-19 vaccination, and SARS-CoV-2. Case presentation: A 21-year-old woman was referred to us after experiencing loss of visual acuity in her right eye from 10 days ago. She had been using oral contraceptives for 2 years for paramenia before noticing her ophthalmological symptoms. Despite having received two does of the mRNA COVID-19 vaccine, she had contracted COVID-19 with fever, sore throat, cough, low back pain, and general malaise about 40 days before the initial visit. However, only the cough persisted for a month. The right eye showed BRVO with macular edema (ME). She did not smoke or have diabetes mellitus or systemic hypertension. The result of blood test was normal, including the cardiolipin antibody IgG. She was treated with an intravitreal aflibercept injection immediately. The right fundus showed rapid improvement in the resolution of ME. Conclusions The combination of oral contraceptive use, COVID-19 vaccination, and subsequent SARS-CoV-2 infection could accelerate VTE, thereby leading to BRVO. Given that cases of COVID-19 have increased globally, patients with RVO who use oral contraceptives are likely to be encountered more frequently.

show abstract

Bilateral branch retinal vein occlusion following the diagnosis of mild coronavirus disease

Cited by 4 publications

References 11 publications

The spectrum of COVID-19-associated chorioretinal vasculopathy

The spectrum of COVID-19-associated chorioretinal vasculopathy

Case Report: Branch retinal vein occlusion following COVID-19 vaccination and SARS-CoV-2 infection while taking oral contraceptives

Development of Branch Retinal Vein Occlusion Following COVID-19 Vaccination and Subsequent SARS-CoV-2 Infection While Taking Oral Contraceptives

Contact Info

Product

Resources

About